Below are the candidate companies in the pharma, biotech and life sciences sector for the Most Admired Corporate Dealmakers survey. They were determined statistically, and represent a roll-call of the most transaction-intensive large companies in the sector. We screened for the companies in the sector that closed the highest number and dollar value of acquisitions and divestitures between January 1, 2006 and June 30, 2009. The selection formula also recognized companies for doing a high dollar volume of deals compared to their market capitalizations on the start date. To be included, companies had to have a market cap of $5 billion or more on the closing date of the study period. To see a list of the company's deals in the period, click on the company's name.
To participate in the Most Admired Corporate Dealmakers Survey, go to www.thedeal.com/cdsurvey
| Pharmaceuticals, biotech and life sciences sector market caps |
Market cap |
($mill.) |
% change |
1/1/06 |
$982,844 |
-16% |
6/1/09 |
$828,341 |
Total aggregate market cap numbers reflect all U.S. based public pharmaceuticals, biotech and life sciences companies trading on primary U.S. exchanges with market cap values on both 1/1/06 and 6/30/09 |
| |
Company |
No. buys |
Total value of buys ($mill.) |
No. sells |
Total value of sells ($mill.) |
Total no. deals |
Total value of deals ($mill.) |
Market cap (1/1/06) |
Market cap (6/30/09) |
Total value of deals as a % of market cap 1/1/06 |
% change in market cap |
| Johnson & Johnson |
7 |
$20,332 |
3 |
$440 |
10 |
$20,772 |
$187,503 |
$156,516 |
11.1% |
-17% |
| Pfizer Inc. |
7 |
3,086 |
6 |
17,067 |
13 |
20,153 |
171,901 |
101,220 |
11.7 |
-41 |
| Bristol-Myers Squibb Co. |
2 |
810 |
6 |
11,134 |
8 |
11,944 |
44,961 |
40,232 |
26.6 |
-11 |
| Abbott Laboratories |
6 |
11,205 |
1 |
360 |
7 |
11,565 |
61,165 |
72,698 |
18.9 |
19 |
| Eli Lilly & Co. |
6 |
9,916 |
2 |
83 |
8 |
9,999 |
64,322 |
39,802 |
15.5 |
-38 |
| Gilead Sciences Inc. |
5 |
3,951 |
2 |
6 |
7 |
3,957 |
24,073 |
42,456 |
16.4 |
76 |
| Celgene Corp. |
3 |
2,753 |
0 |
0 |
3 |
2,753 |
11,016 |
22,020 |
25.0 |
100 |
| Merck & Co. |
6 |
1,944 |
3 |
685 |
9 |
2,629 |
69,557 |
58,961 |
3.8 |
-15 |
| Genzyme Corp. |
3 |
936 |
1 |
620 |
4 |
1,556 |
18,277 |
15,018 |
8.5 |
-18 |
| Allergan Inc. |
4 |
1,038 |
0 |
0 |
4 |
1,038 |
14,494 |
14,488 |
7.2 |
0 |
|
Join Corporate Dealmaker's LinkedIn forum
|
Juergen Lasowski
And the winners are...
